- Home
- SOUNW vs YDESW Comparison
SOUNW vs YDESW Comparison
Compare SOUNW & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOUNW | YDESW |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | 954 | 15 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOUNW | YDESW |
|---|---|---|
| Price | $1.90 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 20.5K | 4.6K |
| Earning Date | 02-27-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,297,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.05 | N/A |
| 52 Week Low | $1.60 | $0.25 |
| 52 Week High | $10.82 | $2.85 |
Technical Indicators
Market Signals| Indicator | SOUNW | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 40.70 |
| Support Level | $1.60 | N/A |
| Resistance Level | $2.89 | $0.58 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 26.80 | 41.62 |
Price Performance
Historical ComparisonAbout SOUNW SoundHound AI Inc. Warrant
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
About YDESW YD Bio Limited Warrants
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.